Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Steven Gore"'
Publikováno v:
BMC Bioinformatics, Vol 25, Iss 1, Pp 1-13 (2024)
Abstract As noncommunicable diseases (NCDs) pose a significant global health burden, identifying effective diagnostic and predictive markers for these diseases is of paramount importance. Epigenetic modifications, such as DNA methylation, have emerge
Externí odkaz:
https://doaj.org/article/e4faaa57b82e4d78833d3ba184bbf390
Autor:
Jan Bewersdorf, Rory M. Shallis, Elad Sharon, Anne Caldwell, Wei Wei, Abdulraheem Yacoub, Yazan Madanat, Joshua Zeidner, Jessica Altman, Olatoyosi Odenike, Swaroopa Yerrabothala, Tibor Kovacsovics, Nikolai Podoltsev, Stephanie Halene, Richard Little, Richard Pierkarz, Steven Gore, Tae Kon Kim, Amer M. Zeidan
Publikováno v:
HemaSphere, Vol 7, p e30347e2 (2023)
Externí odkaz:
https://doaj.org/article/02ba96f59abf43b6b9098d18bc20d32c
Autor:
Steven Gore, Rajeev K. Azad
Publikováno v:
BMC Bioinformatics, Vol 23, Iss 1, Pp 1-17 (2022)
Abstract Background Despite remarkable advances in cancer research, cancer remains one of the leading causes of death worldwide. Early detection of cancer and localization of the tissue of its origin are key to effective treatment. Here, we leverage
Externí odkaz:
https://doaj.org/article/40914c7adde64d9fa0787da2846ac3c6
Autor:
Frances Chow, Michael Berens, Sharon Tamir, Yosef Landesman, Christopher Walker, Mark Krailo, Steven Gore, Jana Portnow
Publikováno v:
Journal of Clinical and Translational Science, Vol 7, Pp 126-126 (2023)
OBJECTIVES/GOALS: Selinexor is a novel XPO1 inhibitor that blocks nuclear export, thus impairing DNA repair and causing apoptosis. Our goal was to conduct preclinical and clinical studies to test our hypothesis that selinexor’s efficacy is boosted
Externí odkaz:
https://doaj.org/article/3b387fb5faa140c6aeea72dc7a79b29e
Publikováno v:
Biomedical chromatography : BMCREFERENCES. 36(11)
Ataxia-telangiectasia-mutated and Rad3-related (ATR) is master regulator of the DNA-damage response that, through multiple mechanisms, can promote cancer cell survival in response to replication stress from sources, including chemotherapy and radiati
Autor:
Aman Chauhan, Jill Kolesar, Donglin Yan, Daneng Li, Aman Khurana, William Edgar Carson, Susanne M. Arnold, Steven Gore, Larry Rubinstein, Elise C. Kohn, Percy Ivy, Ying Xiao, Yuni Dewaraja, Heloisa P. Soares, Jan Hendrik Beumer, Bhavana Konda, Vineeth Sukrithan, Lowell Brian Anthony
Publikováno v:
Journal of Clinical Oncology. 41:TPS658-TPS658
TPS658 Background: Radiolabeled somatostatin analogues provide a means of delivering targeted radiation with a high therapeutic index to NETs that express somatostatin receptors (SSTRs). Radiolabeled somatostatin analogue Lutetium 177 DOTATATE (Lutat
Publikováno v:
Cancer Genetics. :12
Autor:
Ryan Leibrandt, Paul Henry Frankel, Jan Hendrik Beumer, Naoko Takebe, Ming Yin, Hamid Emamekhoo, Primo \\'Lucky\\' N. Lara, Steven Gore, Mamta Parikh
Publikováno v:
Journal of Clinical Oncology. 40:TPS3174-TPS3174
TPS3174 Background: Cisplatin, a well-established backbone of combination therapy of various advanced solid tumors, inhibits DNA synthesis by forming DNA cross-links and adducts. Despite the activity of cisplatin, tumor cells can either be refractory
Autor:
Liza C Villaruz, Karen Kelly, Saiama Naheed Waqar, Elizabeth J. Davis, Geoffrey Shapiro, Patricia LoRusso, Elizabeth Claire Dees, Daniel Paul Normolle, John C. Rhee, Edward Chu, Steven Gore, Jan Hendrik Beumer
Publikováno v:
Journal of Clinical Oncology. 40:3012-3012
3012 Background: Ataxia telangiectasia and Rad3 related (ATR) is activated in response to replication stress from topoisomerase 1 inhibitors. Selective ATR inhibition with berzosertib potentiates the efficacy of irinotecan in colorectal mouse xenogra
Autor:
Joaquina Celebre Baranda, Gary C. Doolittle, Rahul Atul Parikh, Anup Kasi, Elizabeth Marie Wulff-Burchfield, Benjamin Powers, Robert E. Pluenneke, Marc Steven Hoffmann, Abdulraheem Yacoub, Anwaar Saeed, Larry R. Corum, Tara L. Lin, Weijing Sun, Margaret M. Mooney, Jeffrey Moscow, James H. Doroshow, Brittany Waters, S. Percy Ivy, Steven Gore, Roy A. Jensen
Publikováno v:
Journal of Clinical Oncology. 40:6542-6542
6542 Background: Access to health care including clinical trials (CT) leading to paradigm-changing cancer treatments are critical for high quality cancer care and equity in society. In this report, we highlight methods in accruing to ETCTN wherein un